PHASIC COURSE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ACCORDING TO THE LIPID PEROXIDATION PRODUCTS (the review and own results)

Authors

  • Dorosh E. G. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine

DOI:

https://doi.org/10.21856/j-PEP.2013.4.08

Keywords:

non-alcoholic fatty liver disease, type 2 diabetes mellitus, lipid peroxidation, conjugated dienes

Abstract

t was introduced the review of the literature on the diagnosis of stages of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (DM). In the result of his own research was found the phasic course of NAFLD in patients with type 2 DM based on the levels of conjugated dienes (CD), and based on the study of their interrelationship with parameters of protein, lipid and carbohydrate metabolism. At the CD level of 200–400 nmol/l there is a steatosis stage, at the 400–600 nmol/l — steatohepatitis, at the 600 nmol/l or more — fibrotic changes in the liver. Using of the results of this study in clinical practice will allow non-invasive way to determine the stage NAFLD in patients with type 2 DM. This will expand the ability of diagnose this disease and provide early detection of pathological changes in the liver.

References

Hazanov AI. Ros Zhurn Gastrojenterologii, Gepatologii, Koloproktologii 2005; 15(2):26-32.

Festi D, Colecchia A, Sacco T, et al. Obes Rev 2004; 5(1):27-42.

Lazo M, Clark J. Semin Liver Dis 2008; 28(4):339-350.

Browning J, Szczepaniak L, Dobbins R, et al. Hepatology 2004; 40: 1387-1395.

Musso G, Gambino R, Cassader M. Obes Rev 2010; 11(6):430-445.

Nikitin IG. Ros Med Vesti 2010; 15(1):41-46.

Stefan N, Kantartzis K, Häring H. Endocrine Rev 2008; 29(7):939-960.

Butrova SA, Eliseeva AJu, Il’in AV. Ozhirenie i Metabolizm 2008; 2(15):17-21.

Ivashkin VT, Shul’pekova Ju O. RMZh Bolezni Organov Pishhevarenija 2000; 2:41-45.

Karnejro de Mura M. Klin Perspektivy Gastrojenterologii, Gepatologii 2001; 3:12-15.

Shhekina MI. Consilium Medicum 2009; 8(11):37-39.

Dixon JB, Bhathal PS, Hughes NR, et al. Hepatology 2004; 39:1647-1654.

Marchesini G, Marzocchi R, Agostini F, et al. OpinLipidol 2005; 16(4):421-427.

Bugianesi E, Zannoni C, Vanni E, et al. Dig Liver Dis 2004; 36(3):165-173.

Butrova SA. Rus Med Zhurn 2001; 9:56-60.

Garg A, Misra A. J Clin Endocrinol Metab 2002; 87(7):3019-3022.

Silverman EM, Sapala JA, Appelman HD. Am J Clin Pathol 1995; 104: 23-31.

Ametov AS. Problemy Jendokrinologii 2002; 3:31-36.

Tkachenko EI, Uspenskij JuP, Belousova LN, Petrenko VV. Jeksperim i Klin Gastroenterologija 2008; 2:92-96.

Augulo P. N Engl Y Med 2002; 346:1221-1231.

Klimovich II, Doroshenko EM, Strapko VP, Smirnov VJu. Zhurn GrGMU 2008; 1:14-21.

Lewis JR. Mohanty SR. Digestive Dis Sci 2010; 55:560-578.

Torer N, Ozenirler S, Yucel A, et al. Scand J Gastroenterol 2007; 42(9):1095-1101.

Milner K, Van der Poorten D, Xu A, et al. Hepatology 2009; 49(6): 1926-1934.

Kawata S. Clin J Gastroenterol 2008; 1(1):1-6.

Mehtiev SN, Grinevich VB, Kravchuk JuA, et al. Lechashhij Vrach 2008; 2:29-37.

Bogomolov P, OCodikov GV. Spravochnik Poliklinicheskogo Vracha 2006; 4(1):2.

Tkach SM. Zdorov’ja Ukrai’ny 2008; 22:64-65.

Kleiner DE, Brunt EM, Van Natta M, et al. Hepatology 2005; 41: 1313-1321.

Shafrir E, Raz I. Diabetologia 2003; 46(46):433-440.

Weickert MO, Pfeiffer AFH. Diabetologia 2006; 49:1732-1741.

Bogomolov PO, Pavlova TV. Farmateka 2003; 10:31-39.

Adams LA, Angulo P, Lindor KD. CMAJ 2005; 172(7):899-905.

Bugianesi E, Vanni E, Marchesini G. Curr Diab Rep 2007; 7:175-180.

Leuschner U. Non-alcoholic Steatohepatitis (NASH), Freiburg, 2010: 39 p.

Mofrad P, Contos M, Haque M. Hepatology 2003; 37:1286-1292.

Adams LA, Zein CO, Angulo P, et al. Am J Gastroenterol 2004; 99: 2365-2368.

El-Serag HB, Everhart JE. Gastroenterology 2002; 122:1822-1828.

Fong DG, Nehra V, Lindor KD, et al. Hepatology 2000; 32:3-10.

Mehta R, Thomas E, Bell J, et al. Wld J Gastroenterol 2008; 14(22): 3476-3483.

Hardwick RN, Fisher CD, Canet MJ, et al. Drug Metab Dispos 2010; 38(12):2293-2301.

Downloads

Published

2013-12-20

How to Cite

Dorosh, E. G. (2013). PHASIC COURSE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS ACCORDING TO THE LIPID PEROXIDATION PRODUCTS (the review and own results). Problems of Endocrine Pathology, 46(4), 63-77. https://doi.org/10.21856/j-PEP.2013.4.08